A team at Guy’s and St Thomas’ NHS Foundation Trust in London set out to close this gap with a structured, age-adapted initiative known as the GOLD diabetes enhanced monitoring pathway, developed within the Geriatric Oncology Liaison Development clinic. Reporting their work in the European Geriatric Medicine journal, the researchers describe a quality improvement project conducted between February 2022 and June 2025, in which a multidisciplinary group of geriatricians, oncologists, diabetologists and clinical nurse specialists translated national guidance from the UK Chemotherapy Board and the Joint British Diabetes Societies for Inpatient Care into a practical, locally tailored system for older patients at intermediate risk of steroid-induced hyperglycaemia.

The pathway began with careful risk stratification. Patients were classified as low risk if they had an HbA1c below 48 mmol/mol and no history of diabetes, and were followed by their oncology team and general practitioner. High-risk patients, including those on insulin, those with HbA1c of 64 mmol/mol or above, glucose readings of 15 mmol/L or higher, pancreatic cancer, or a previous episode of steroid-induced hyperglycaemia, were referred directly to specialist diabetes services. The intermediate group, typically those with HbA1c between 48 and 63 mmol/mol or capillary glucose between 11 and 14.9 mmol/L, or patients with diabetes managed on oral agents who did not meet high-risk criteria, became the focus of the GOLD pathway.

Once enrolled, each patient received a capillary blood glucose meter and personalised education from a geriatric clinical nurse specialist, delivered face to face or by telephone within days of referral, because the interval between referral and the start of systemic anti-cancer therapy is often extremely short. Education covered the symptoms of high and low blood sugar, how to recognise diabetes emergencies, glucose targets, and practical demonstrations of the meter, all calibrated to each patient’s health literacy, cognition and physical abilities, with caregivers involved where necessary. During every treatment cycle, patients checked their glucose on the day of steroid administration and the following two days, before breakfast and before the evening meal, a schedule designed to capture the late-afternoon and evening peaks characteristic of steroid-induced hyperglycaemia.

Telephone follow-up by nurse specialists after each cycle formed the backbone of the monitoring system. The team reviewed all glucose readings, assessed food intake and treatment side effects, and applied decision-making algorithms for intervention. Hyperglycaemia was defined as at least two readings above 15 mmol/L, and hypoglycaemia as any reading below 4 mmol/L. When medication was required, the protocol favoured gliclazide, a sulphonylurea that directly stimulates insulin secretion and thereby counteracts the steroid-driven suppression of pancreatic beta-cell function. The team deliberately adopted a higher intervention threshold of 15 mmol/L, compared with the 12 mmol/L in national guidance, reflecting broader glycaemic targets for older people and a conscious effort to avoid hypoglycaemia and its consequences, particularly in patients with poor oral intake or renal impairment.

The implementation itself was iterative. The pathway was refined through seven Plan-Do-Study-Act cycles between 2022 and 2023, each incorporating feedback from healthcare professionals and addressing specific local barriers such as the feasibility of glucose measurement, intervention thresholds and the medication titration process. Risk criteria were sharpened over successive cycles, with the glucose range adjusted from 12–20 to 11–15 mmol/L and the HbA1c range expanded from 48–59 to 48–64 mmol/mol. Fortnightly multidisciplinary meetings were introduced from January 2023 to review complex cases, and the geriatric nursing team grew increasingly autonomous in managing intermediate-risk patients, reducing the burden on specialist diabetes services while retaining rapid access to expert advice.

In total, 126 patients were enrolled, with a median age of 74 years, 58% male, and 77% living with pre-existing diabetes. The most common tumour sites were the oesophagus, colon and breast, and 94% received chemotherapy as their primary systemic anti-cancer therapy, most commonly supported by dexamethasone at a median daily dose of 8 mg for the first four days of each cycle, chiefly for its anti-emetic and anti-allergic properties. Comprehensive geriatric assessment data, available for 81% of participants, revealed a largely pre-frail population with a median Clinical Frailty Scale score of 3, and identified malnutrition in 46% of the cohort, alongside social isolation, functional impairment and recent falls in smaller proportions. Personalised geriatric interventions, spanning physiotherapy, occupational therapy, dietary support and medication management, were implemented for the vast majority of those with identified impairments.

The results paint a picture of a pathway that is both feasible and safe. Clinical advice on diabetes management was provided to 89% of patients, and diabetes medication intervention was required in 32%, with gliclazide initiated or escalated in 92% of those cases. Women and patients with pre-existing diabetes were significantly more likely to need medication. Critically, only three hypoglycaemic events occurred, all asymptomatic and all managed without clinical consequences. Among 35 unplanned hospital admissions within a year, only two were related to hyperglycaemia, and there were no episodes of diabetic ketoacidosis or hyperosmolar hyperglycaemic syndrome, and no admissions for hypoglycaemia. During a median follow-up of 300 days, 41 patients died, but mortality was associated with metastatic disease, malnutrition and social isolation rather than with glycaemic control or diabetes intervention, suggesting that proactive metabolic monitoring did not add risk in this fragile population.

The pathway also influenced cancer treatment itself in measurable ways. Steroid regimens were modified for 24% of patients, almost always involving dose reductions driven by hyperglycaemia, and in 80% of those cases the adjustment was linked to the need for diabetes medication. While steroid reduction triggered treatment toxicity symptoms in four patients, leading to early discontinuation or dose reduction of the anti-cancer protocol in two, the overall signal was one of balance: oncologists could taper steroids with confidence knowing that a safety net existed for the metabolic consequences. Notably, secondary referrals to the diabetes team fell dramatically over the project period, from 36% of patients enrolled in 2022 to just 5% in 2025, evidence that the geriatric team’s growing expertise was absorbing demand that would otherwise have overwhelmed specialist services.

The authors are candid about limitations. The single-centre design, the predominance of pre-frail patients, the absence of a comparator group and the use of clinical rather than validated tools for some geriatric domains all constrain generalisability, and under-ascertainment of nocturnal or asymptomatic glycaemic excursions cannot be excluded with intermittent fingerstick testing. Even so, the team argues that the GOLD pathway offers a robust, patient-centred model for integrating geriatric, oncology and diabetes care, aligned with national and international recommendations for multidisciplinary management of older adults with complex needs. Future priorities include multi-centre validation, comparative and randomised designs to confirm effectiveness, integration of continuous glucose monitoring and digital health tools to reduce nursing workload, evaluation of patient-reported outcomes and cost-effectiveness, and incorporation of patient feedback to improve usability for those who struggle with glucometer technology. If those steps succeed, structured diabetes monitoring could become a standard component of geriatric oncology, ensuring that the steroids that help fight cancer no longer silently undermine the patients receiving them.

Subject of Research: A quality improvement project evaluating an age-adapted, multidisciplinary diabetes monitoring pathway for older adults with cancer undergoing steroid-based systemic anti-cancer therapy.

Article Title: Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy

Article References: Liuu, E., Evans, R., Bassas-Letissier, N., Amaratunga, G., Compton, S., Georgiou, A., Kalsi, T., Liu, Y.-F., Maguire, J., Nottage, C., Rush, H. L., & Welch, C. (2026). Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01585-w

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01585-w

Keywords: geriatric oncology, diabetes, steroid-induced hyperglycaemia, systemic anti-cancer therapy, quality improvement, multidisciplinary care, gliclazide, blood glucose monitoring, older adults, comprehensive geriatric assessment, hypoglycaemia, cancer treatment

The study set out to answer a deceptively simple question: what happens to the somatic mutations already present in normal tissue when a patient undergoes treatment for cancer? Chemotherapy and radiotherapy are designed to kill rapidly dividing malignant cells, but they also expose the surrounding normal tissue to powerful DNA-damaging agents and growth pressures. The researchers reasoned that these pressures should act as a selective filter, favoring any normal cells whose preexisting mutations happen to confer survival advantages under treatment conditions.

Using deep sequencing of normal esophageal epithelium, the team compared the mutational landscapes of patients who had received cancer therapy with those who had not. The analysis focused on clonal expansions — the visible footprints left behind when a single mutant cell divides into a visible population of descendants. In untreated individuals, the dominant clones were largely shaped by age-related selection, with mutations in genes such as NOTCH1 frequently outcompeting wild-type tissue simply by conferring a growth advantage in the aging esophagus.

After cancer treatment, however, the picture changed markedly. The spectrum and composition of mutant clones in normal tissue were measurably altered, with certain mutations rising to prominence precisely because they helped their host cells withstand the assault of therapy. The data indicate that treatment does not simply create these mutants de novo in most cases; rather, it selects for mutants that were already present at low frequencies before therapy began. In evolutionary terms, cancer therapy acts as a strong selective sweep applied to a pre-populated landscape of somatic variation.

One of the most consequential findings concerns mutations in genes that are themselves the targets of existing drugs — so-called druggable mutants. The study reports that some of these treatment-resilient clones carry alterations that would, in a tumor setting, justify targeted therapy. The paradox is uncomfortable: a treatment intended to eliminate cancer can enrich, in the surrounding normal tissue, mutant lineages that bear the hallmarks of drug resistance and survival resilience. These enriched normal clones persist after therapy, potentially reshaping the long-term biology of the organ.

Technically, the work relied on high-depth targeted sequencing and mutational signature analysis, approaches that allow researchers to distinguish mutations caused by therapy-induced DNA damage from those that predate treatment. Mutational signatures — characteristic patterns of base changes left by distinct mutational processes such as platinum chemotherapy or radiation — served as a molecular timestamp. By reading these signatures, the team could show that many of the clones enriched after therapy carried mutations acquired years earlier, which then expanded under the new selective conditions created by treatment.

The findings speak to a broader concept in modern oncology and somatic genetics: the idea of cancer therapy as an evolutionary force acting on the whole organism, not merely on the tumor. Normal tissues across the body accumulate mutations steadily with age, and the esophagus is exceptional in the sheer density of mutant clones it harbors. When cytotoxic therapy sweeps through the body, it does not distinguish cleanly between malignant growth and advantaged normal lineages. Cells in normal tissue that can survive the insult, repair the damage, or proliferate afterward will predictably come to occupy more of the tissue.

This reframing has practical implications for how clinicians think about the late effects of cancer treatment. Long-term survivors of chemotherapy and radiotherapy are known to face elevated risks of second cancers in and near the treatment field. The new results suggest a mechanistic route for part of that risk: therapy-driven expansion of mutant clones in normal tissue may enlarge the population of cells standing ready to acquire the remaining mutations needed for full malignant transformation. A larger target population, in principle, raises the probability that transformation events will occur during the decades of life that follow successful treatment.

The study also adds nuance to debates about surveillance and prevention. If druggable mutants can be enriched in normal tissue by therapy, then monitoring the clonal composition of normal epithelium after treatment could, in future, help stratify patients by their reservoir of treatment-resilient clones. Conversely, the observation raises questions about whether certain therapy regimens could be tailored to minimize the selection of high-risk clones in critical organs. Such applications remain speculative, but the study establishes the principle that clonal dynamics in normal tissue are a measurable and modifiable consequence of cancer care.

For the field of somatic evolution, the work reinforces a lesson that has been building for years: the boundary between normal and cancerous tissue is not a simple genetic divide but a continuum shaped by ongoing selection. The esophagus of a treated cancer patient is not the same organ, in evolutionary terms, as the esophagus of an untreated person of the same age. Therapy rewrites the competitive hierarchy among resident mutants, and the winners of that rewritten contest carry scars — and sometimes survival advantages — that could shape the patient’s health for decades to come. Understanding and eventually managing this hidden evolution may become an integral part of cancer survivorship.

The concept underlying this study has an instructive parallel in the blood. Clonal hematopoiesis, the age-related expansion of mutant blood cell lineages, was shown in recent years to be accelerated by chemotherapy, with certain cytotoxic agents favoring clones carrying mutations in DNA-damage response genes such as TP53 and PPM1D. The new esophageal findings extend this principle to an epithelial organ, suggesting that therapy-driven selection of preexisting somatic mutants may be a general feature of how cytotoxic treatment interacts with aging tissues throughout the body. What differs between tissues is which genes matter: in the esophagus, the selective landscape appears dominated by lineages whose advantages lie in survival and repopulation rather than in a single canonical chemotherapy-resistance pathway.

The evolutionary logic at work is a familiar one to population biologists. Standing genetic variation within a population allows rapid adaptation when the environment shifts, because the favorable variants need not wait for new mutations to arise. The esophagus supplies abundant standing variation: sequencing studies of normal esophageal epithelium have found that by the seventh decade of life, a large fraction of the lining is occupied by mutant clones, many carrying mutations in genes under strong positive selection such as NOTCH1, PIK3CA, and TP53. Against this backdrop, a course of chemotherapy or radiotherapy functions as an environmental catastrophe of precisely the kind that reshuffles competitive hierarchies. Clones that were minor participants before treatment can emerge as dominant occupants of the tissue afterward, not because they acquired new advantages during therapy, but because the advantages they already possessed suddenly became decisive.

The distinction between selection and induction is central to interpreting the results, and the mutational signature evidence is what makes the distinction possible. Platinum-based chemotherapy, for example, leaves a recognizable imprint of specific base substitutions, while ionizing radiation produces characteristic patterns of small deletions and structural changes. If treatment were primarily creating new mutant clones, the enriched lineages should carry therapy-associated signatures in the very mutations driving their expansion. Instead, the study’s reading of these molecular timestamps indicates that the driver mutations in enriched clones largely predate exposure, with therapy-associated damage appearing only as secondary background. This ordering matters for risk assessment: the reservoir of potentially selectable mutants is established decades before treatment, during the ordinary accumulation of somatic mutations with age, which means the composition of that reservoir at the time of diagnosis may already shape the evolutionary consequences of whatever therapy follows.

The enrichment of druggable mutants in normal tissue deserves particular attention. In oncology, the term druggable usually signals an opportunity: a mutation in a kinase or other signaling protein that a targeted inhibitor can attack. But the same alterations, when present in expanded normal clones, complicate that picture. A normal lineage carrying an activating mutation in a growth-promoting pathway has, by definition, a proliferative or survival edge, and the study indicates that some such lineages are precisely the ones favored under treatment. Whether these clones represent a meaningful precursor state for later malignancy, or remain benign passengers indefinitely, is a question the study raises but cannot fully resolve. Longitudinal sampling of survivors will be needed to determine how stable these treatment-enriched populations are, and whether their persistence correlates with clinically meaningful outcomes.

There is also a methodological lesson embedded in the work. Much of what is known about the somatic genetics of cancer treatment comes from sequencing tumors before and after therapy, an approach that necessarily views evolution through the lens of the malignant population. Sequencing the adjacent normal tissue offers a complementary view of the same selective event from the perspective of the bystanders. The two views can diverge in informative ways, because the pressures experienced by normal epithelium in a treated field differ from those experienced by a tumor with its own evolving defenses. Building a complete picture of therapy as an evolutionary force will likely require attending to both.

Finally, the findings arrive at a moment when the population of long-term cancer survivors is growing steadily worldwide. As more people live decades beyond curative treatment, the late biological consequences of therapy become a public health question in their own right. This study does not settle those questions, but it demonstrates that the somatic evolution of normal tissue is a measurable consequence of cancer care, and therefore a legitimate target for monitoring, modeling, and eventually perhaps intervention.

Subject of Research: How cancer treatment changes the selection of preexisting somatic mutations in normal esophageal tissue

Article Title: Cancer treatment alters mutant selection in normal esophagus

Article References: Fowler, J. C., Arbore, G., Sood, R. K., Abnizova, I., Albarello, L., Pickering, O., Murai, K., Banerjee, U., Brunon, S., Ong, S. H., Cossu, A., Elmore, U., Puccetti, F., Fernandez-Antoran, D., Tonon, G., Dellabona, P., Rosati, R., Hill, S. L., Underwood, T., … Jones, P. H. (2026). Cancer treatment alters mutant selection in normal esophagus. Nature Genetics. https://doi.org/10.1038/s41588-026-02738-0

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02738-0

Keywords: esophagus, somatic mutations, clonal evolution, cancer treatment, chemotherapy, radiotherapy, mutational signatures, drug resistance, NOTCH1, normal tissue, Nature Genetics, second cancers

In current practice, the ice ball created by a cryoablation probe is a central visual guide. Imaging can show the approximate volume of frozen tissue, allowing operators to position applicators and judge whether the tumor is covered. Yet the outer boundary of an ice ball does not necessarily reveal the distribution of temperatures inside it. The temperatures commonly used as lethal benchmarks, around −20 °C to −40 °C, cannot be directly visualized in routine treatment images. As power is reduced to prevent the ice from reaching a vulnerable structure, the overall ice ball may remain similar in size while its colder internal isotherms contract. The result can be a larger marginal zone, spanning temperatures from roughly 0 °C to the lethal threshold, where cells experience sublethal stress and may recover. The CCD model is designed to address that uncertainty by asking not simply whether a location lies inside the ice ball, but whether it has accumulated sufficient time at or below the cell type’s lethal threshold.

The researchers developed the model through a systematic review conducted under PRISMA 2020 guidelines. Searches of PubMed, Embase and Web of Science, covering the available literature through March 2025, identified studies reporting the effects of freeze duration, cell-specific lethal thresholds, lethal isotherm ratios or outcomes associated with particular treatment protocols. Two reviewers independently screened the records, and 43 studies met the inclusion criteria. The evidence base comprised 24 in vitro studies, nine in vivo studies, seven clinical studies and three reviews. CCD was defined as the total time tissue remains at or below its cell-type-specific lethal threshold across all freeze cycles, excluding the intervals used for thawing. For modeling purposes, a point was considered lethally dosed when its accumulated exposure corresponded to a probability of at least 80 percent cell death. The authors describe that level as a conservative lower bound for anatomically constrained treatments, while noting that procedures performed with curative intent and unconstrained margins may require higher targets.

The model’s duration component was calibrated using data from an in vitro study of the transition zone. In that source study, extending exposure from 60 seconds to 120 seconds increased marginal-zone cell death from 42.5 percent to 84.8 percent. The researchers fitted those two points to a logistic curve, using a growth parameter of 0.0538 and a midpoint of 86 seconds. The resulting calculation estimated that a single freeze cycle would need at least 120 seconds to reach the model’s 80-percent cell-death target. Repeating the freeze changed the estimated requirement because processes such as ice recrystallization and incomplete membrane repair during passive thaw can amplify injury between cycles. Under the model’s conservative amplification assumption, the minimum exposure fell to 50 seconds per cycle for a double-cycle protocol and 31 seconds per cycle for a triple-cycle protocol. These values describe effective dose targets in the model, not universally established treatment instructions.

The review also examined how treatment power and ice-ball size affect the spatial distribution of cold. The analysis modeled three cryoablation systems, four ice-ball sizes ranging from 25 to 40 millimeters and power settings between 40 and 100 percent. The calculations assumed that the lethal zone shrinks proportionally as power decreases, although the authors emphasized that this linear relationship has not been fully validated. At 40 percent power, the −20 °C isotherm contracted to approximately 25 to 30 percent of the total ice-ball width. This contraction expanded the marginal zone by as much as 3.9-fold. A visible ice ball could therefore occupy the intended treatment volume while containing a much smaller region exposed to temperatures expected to cause direct lethal injury. Sensitivity analyses using more conservative and more optimistic scaling assumptions changed CCD targets by about 15 to 25 percent, highlighting the uncertainty surrounding the geometry calculations.

The predicted consequences differed according to how resistant the target tissue was to cold. For cold-sensitive tissues, the model found that double-cycle protocols could maintain an adequate cumulative dose across all tested power levels, with estimated exposures of 50 to 125 seconds per cycle. For cold-resistant phenotypes, which may require temperatures near −40 °C for direct lethal injury, most configurations required escalation to triple-cycle protocols, multi-probe overlap or reliance on additional mechanisms of tissue destruction. The analysis found that double cycling increased renal cell lethality from 22 to 62 percent at −10 °C and from 63 to 89 percent at −15 °C in the underlying evidence. It also noted that a meta-analysis involving 786 patients had associated longer freeze duration with better local tumor control. That clinical association supports the importance of time, but it does not by itself prove that the CCD model accurately predicts outcomes for individual patients.

The model offers a practical way to interpret multi-cycle treatment. Under its proposed logic, the first cycle can establish the desired treatment geometry, while later cycles deliver additional biological dose without necessarily expanding the ice ball beyond an anatomical boundary. The source article illustrates this concept with a palliative cryoablation procedure for a 25-millimeter ovarian metastasis near the left psoas, between the L2 and L3 nerve roots. A single applicator was operated at 30 to 40 percent power to constrain the ice ball, and a triple-cycle protocol with passive thawing was used to compensate for the reduced internal isotherms. The first cycle lasted five minutes at 30 percent power, followed by seven minutes at 40 percent and five minutes at 30 percent. The reported procedure produced no observed nerve damage during follow-up. The example demonstrates how the model could rationalize repeated freezing, although one case cannot establish efficacy or safety for broader clinical use.

Important biological limitations remain. Measurements derived from cultured cells cannot be transferred directly to living tumors, where blood flow can carry heat into the treatment margin and shorten the effective duration of cold exposure. This heat-sink effect may be partly offset in later cycles if the first freeze damages blood vessels and reduces local perfusion. Cell type, tissue composition, tumor architecture and temperature history can also influence the response. CCD currently counts time below a fixed threshold rather than assigning a continuous weight to different subzero temperatures. In that respect, it is simpler than the cumulative equivalent minutes at 43 °C model used for hyperthermia, which weights time and temperature continuously. The present calibration relies on only two duration points, the validated duration range is limited to 60 to 120 seconds, and the assumed relationship between power reduction and isotherm contraction remains unconfirmed. The authors therefore present CCD as a structured, testable hypothesis. Prospective studies combining real-time thermometry with volumetric treatment outcomes will be needed before it can guide routine care. If those studies confirm the predictions, cumulative cold dose could give interventional radiologists a quantitative language for choosing freeze duration, cycle number and probe arrangement—especially when tumor control must be balanced against the safety of nearby healthy tissue.
A further implication of the proposed framework is that treatment adequacy would have both spatial and volumetric dimensions. It would not be enough for a few sampled locations to exceed a CCD threshold; the threshold would need to be achieved across a prespecified fraction of the treatment volume. This distinction matters because temperature gradients are steep near the ice-ball margin, and a treatment could contain highly dosed central tissue alongside underdosed peripheral tissue. In principle, thermometry or validated thermal modeling could generate a three-dimensional map of accumulated dose rather than relying on a single visible boundary.

The model also separates the size of the frozen region from its spatial efficiency. The lethal isotherm ratio, or LIR, estimates the proportion of ice-ball width occupied by a selected lethal isotherm. In the reviewed comparisons, the liquid-nitrogen system had the highest reported ratios for a 25-millimeter ice ball, including an approximately 82.6% ratio at −20 °C and 63.3% at −40 °C. By contrast, a larger clustered configuration could produce a greater absolute lethal-zone width while having lower spatial efficiency. These measures therefore answer different planning questions: whether a system can reach a required temperature, how much of the target can be exposed to it, and whether additional cycles or overlapping probes are needed.

CCD may ultimately support adaptive treatment rather than a fixed protocol selected before the procedure. A clinician could begin with a geometry-limited freeze, use measured temperatures or system-specific isotherm estimates to identify underdosed regions, and then adjust cycle duration, power or probe overlap. Such an approach would require reliable calibration for each device and tissue context, because the review combined heterogeneous experimental and clinical evidence. The authors also tested inter-cycle amplification across a broad range and used the conservative end for their principal recommendations, underscoring that the benefit attributed to repeated freezing is not a single settled biological constant. Prospective validation would need to compare predicted dose maps with biopsy, imaging, local-control and toxicity outcomes while accounting for blood flow and temperature measurement error.

Subject of Research: Cumulative cold-dose modeling for cryoablation treatment planning

Article Title: A cumulative cold dosimetry model for cryoablation: from geometry to dose-time planning

Article References: Cornelis, F. H., Cornelis, A. A., & Solomon, S. B. (2026). A cumulative cold dosimetry model for cryoablation: from geometry to dose-time planning. CVIR Oncology, 2(1), Article 20. https://doi.org/10.1007/s44343-026-00058-y

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00058-y

Keywords: cryoablation, cumulative cold dose, cancer treatment, dosimetry, thermal isotherms, cell death, interventional radiology, tumor ablation, cumulative, cold, model, geometry

The pursuit of targeted therapies in oncology has long centered on exploiting weaknesses in cancer DNA repair pathways. Olaparib’s mechanism hinges on synthetic lethality, targeting cells deficient in homologous recombination repair—a key pathway for fixing DNA double-strand breaks. Historically, olaparib’s success has been predominantly documented in tumors harboring germline BRCA1 or BRCA2 mutations, which compromise HR. However, this trial expands the therapeutic horizon to patients whose tumors are HR-deficient through other somatic alterations, yet do not carry inherited BRCA mutations.

Conducted across multiple centers, the EMBRACE trial enrolled patients with metastatic TNBC or platinum-sensitive relapsed ovarian cancer. All participants exhibited HR deficiency, identified through genomic scar assays and functional HRD testing, yet tested negative for germline BRCA1/2 mutations. These inclusion criteria aimed to determine whether HR deficiency alone, regardless of germline mutation status, could predict a favorable response to PARP inhibition.

Results revealed significant antitumor activity of olaparib in this genomically defined subset. Patients demonstrated objective response rates that challenge previous notions of patient eligibility for PARP inhibitors. Importantly, the trial’s findings underscore that platinum sensitivity—a clinical indicator of DNA repair deficiencies—is a crucial factor in predicting treatment response alongside genomic HRD markers.

Safety profiles matched prior olaparib data, showing manageable toxicities with a spectrum typical of PARP inhibitors. Patients tolerated treatment well, with adverse effects primarily including fatigue, nausea, and hematological changes. These findings reaffirm olaparib’s safety in the expanded population and emphasize the potential for wider clinical applicability.

The ramifications of the EMBRACE trial are profound. By decoupling PARP inhibitor therapy from strict dependence on germline BRCA mutations, the study opens avenues for precision medicine approaches in a broader cohort of TNBC and ovarian cancer patients. This could reshape clinical guidelines, advocating for routine HRD testing beyond germline mutation screening to identify candidates for PARP inhibition.

Moreover, the study highlights the importance of integrating molecular diagnostics into treatment algorithms. Approaches using advanced genomic assays to capture HR deficiency are pivotal to optimize patient selection, enhance outcomes, and limit exposure to ineffective therapies. This trial thus represents a step toward more nuanced, biology-driven cancer care.

Future investigations will likely focus on refining HRD detection techniques and combining PARP inhibitors with other targeted agents to overcome resistance mechanisms. As the landscape evolves, the EMBRACE trial’s insights bring renewed optimism for managing some of the most aggressive breast and ovarian cancers.

The application of olaparib beyond germline BRCA-mutated tumors fundamentally alters the therapeutic landscape. Through careful patient stratification based on DNA repair status, oncologists can now consider PARP inhibition for a previously untapped population, potentially improving survival and quality of life for many patients with historically limited options.

Subject of Research: Homologous recombination deficiency and PARP inhibitor therapy in metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline BRCA1/2 mutations

Article Title: Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Article References:
Sjoquist, K.M., Dobrovic, A., Robledo, K.P. et al. Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03535-6

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03535-6